Research Article

Proteomic Analysis of Plasma-Purified VLDL, LDL, and HDL Fractions from Atherosclerotic Patients Undergoing Carotid Endarterectomy: Identification of Serum Amyloid A as a Potential Marker

Antonio J. Lepedda, 1 Gabriele Nieddu, 1 Elisabetta Zinellu, 1 Pierina De Muro, 1 Franco Piredda, 2 Anna Guarino, 3 Rita Spirito, 3 Franco Carta, 4 Francesco Turrini, 5 and Marilena Formato 1

1 DipartimentodiScienzeBiomediche,UniversityofSassari,ViaMuronii25,07100Sassari,Italy
2 Servizio di Chirurgia Vascolare, Clinica Chirurgica Generale, University of Sassari, Viale S. Pietro 43/B, 07100 Sassari, Italy
3 Centro Cardiologico “F. Monzino,” IRCCS, University of Milan, Via Carlo Parea 4, 20138 Milan, Italy
4 Nurex S.r.l., Via Predda Niedda Strada 3, 07100 Sassari, Italy
5 Dipartimento di Genetica, Biologia, Biochimica, University of Turin, Via Santena 19, 10126 Turin, Italy

Correspondence should be addressed to Antonio J. Lepedda; ajlepedda@uniss.it and Marilena Formato; formato@uniss.it

Received 11 October 2013; Revised 18 November 2013; Accepted 20 November 2013

Academic Editor: Joseph Fomusi Ndisang

Copyright © 2013 Antonio J. Lepedda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Apolipoproteins are very heterogeneous protein family, implicated in plasma lipoprotein structural stabilization, lipid metabolism, inflammation, or immunity. Obtaining detailed information on apolipoprotein composition and structure may contribute to elucidating lipoprotein roles in atherogenesis and to developing new therapeutic strategies for the treatment of lipoprotein-associated disorders. This study aimed at developing a comprehensive method for characterizing the apolipoprotein component of plasma VLDL, LDL, and HDL fractions from patients undergoing carotid endarterectomy, by means of two-dimensional electrophoresis (2-DE) coupled with Mass Spectrometry analysis, useful for identifying potential markers of plaque presence and vulnerability. The adopted method allowed obtaining reproducible 2-DE maps of exchangeable apolipoproteins from VLDL, LDL, and HDL. Twenty-three protein isoforms were identified by peptide mass fingerprinting analysis. Differential proteomic analysis allowed for identifying increased levels of acute-phase serum amyloid A protein (AP SAA) in all lipoprotein fractions, especially in LDL from atherosclerotic patients. Results have been confirmed by western blotting analysis on each lipoprotein fraction using apo AI levels for data normalization. The higher levels of AP SAA found in patients suggest a role of LDL as AP SAA carrier into the subendothelial space of artery wall, where AP SAA accumulates and may exert noxious effects.

1. Introduction

Cardiovascular diseases are the leading cause of death and illness in developed countries, with atherosclerosis being the most important contributor. Atherosclerosis is a chronic inflammatory condition that could turn into an acute clinical event due to plaque rupture and thrombosis [1]. Indeed, vascular inflammation not only plays a major role in the development of atherosclerosis but also contributes to the acute onset of thrombotic complications [2]. The selective retention of circulating apolipoprotein B100 containing lipoproteins in the subendothelial space, by means of specific interactions with artery wall proteoglycans, is currently thought to be the leading event in atherogenesis [3, 4].

Lipoproteins are supramolecular complexes that deliver insoluble lipids from the tissues where they are synthesized to those that metabolize or store them. They consist of hydrophobic molecules (core), particularly triacylglycerol...
and cholesteryl esters, stabilized by a coat of amphipathic compounds, namely, phospholipids, unesterified cholesterol, and proteins, with the latter referred to as apolipoproteins (apo) [5]. Apolipoproteins are a very heterogeneous protein family implicated in lipoprotein stabilization, lipid metabolism, inflammation, or immunity [6]. Except for apo B100, the main structural apolipoprotein of VLDL and LDL, they may be exchanged among circulating lipoprotein classes during their physiological metabolism or in pathological conditions. For a long time now, lipoproteins have attracted a great deal of interest because of their implication in atherogenesis. Although it is well known that high LDL-cholesterol and low HDL-cholesterol levels are associated with increased risk for the development of cardiovascular disease, clinical studies suggest that levels of apo B100 and apo AI may be better predictors [7]. Since the protein component of these particles is largely responsible for carrying out their various functions, detailed information about the apolipoprotein composition and structure may contribute to revealing their role in atherogenesis and to developing new therapeutic strategies for the treatment of lipoprotein-associated disorders. Applying proteomics to the study of lipoproteins, including gel-based or gel-free technologies, may significantly contribute to the achievement of this goal. Indeed, recent proteomic studies have revealed that lipoproteins carry an array of proteins previously unexpected [8].

As far as we know, about thirty proteomic studies on VLDL, LDL, and HDL have been published up to now, while no proteomic studies on chylomicrons are reported in the literature [8]. Recently, the proteome of lipoprotein (a) has been investigated too [9]. The majority of these studies focused on characterizing the apolipoprotein cargo of the different lipoprotein fractions in healthy subjects. Conversely, only few studies dealt with differential apolipoprotein expression in relation to cardiovascular diseases. In this respect, HDL fraction has been the most studied, in association with coronary artery disease (CAD) [10–13], high cardiovascular risk and acute myocardial infarction [14], hyperlipidemia [15], or low levels of HDL cholesterol [16, 17]. One study on LDL fraction from atherosclerotic patients with the metabolic syndrome and diabetes [18] and one on VLDL fraction from hyperlipidemic subjects [19] were conducted. Several apolipoprotein isoforms involved in lipid metabolism, inflammation or immunity were detected as differentially expressed. Regrettably, these studies merely focused on one lipoprotein class at a time and were based on a low sample size.

Recently, by applying proteomics to the study of carotid plaque vulnerability, we identified a panel of proteins differentially expressed/oxidized in stable and unstable lesions [20, 21]. In the present study we set up a method for characterizing the exchangeable apolipoprotein component of plasma VLDL, LDL, and HDL fractions from patients undergoing carotid endarterectomy, useful for identifying differentially expressed proteins with respect to healthy normolipidemic subjects. By means of two-dimensional electrophoresis (2-DE) and MALDI-TOF MS analysis we identified acute-phase serum amyloid A protein (AP SAA) as overexpressed in the three lipoprotein classes from patients. Results validation was performed by western blotting analysis. In our knowledge, this is the first study providing information on exchangeable apolipoprotein profiles in VLDL, LDL, and HDL fractions from atherosclerotic patients undergoing carotid endarterectomy.

### 2. Materials and Methods

#### 2.1. Sample Collection

Analyses were performed on 4 pooled plasma samples from 57 healthy normolipidemic volunteers and 4 pools obtained from 79 patients undergoing carotid endarterectomy. Carotid atherosclerosis was assessed by ultrasonography using a Mylab 70 X vision echocolor Doppler equipped with an LA332 Apple Probe 11–3 MHz (Esaote). All patients selected for surgery had either a high-grade stenosis (>70%) or an ulcerated lesion of a medium grade based on echo-Doppler analysis. All patients with hypertension, dyslipidemia, and/or diabetes were under pharmacological treatment. The main clinical parameters of patients and controls are summarized in Table 1. Informed consent was obtained before enrolment. Institutional Review Board approval was obtained. The study was conducted in accordance with the ethical principles of the current Declaration of Helsinki.

Fasting blood samples were collected into Vacutainer tubes containing EDTA and immediately centrifuged at 2000 ×g for 10 minutes at 4°C. Plasma was added with 100 μM APMSF (4-amidinophenylmethane-sulfonylfluoride), 2 μg/mL Kallikrein Inactivator (cyclohexylacetyl-Phe-Arg-Ser-Val-Gln amide), and 50 μM leupeptin (Acetyl-Leu-Leu-Arg-Hydrochloride) and stored at −80°C until analysis. Before lipoprotein purification, equal amounts of plasma samples were randomly combined to yield 4 homogeneous pooled VLDL, LDL, and HDL fractions from both patients and controls.

#### 2.2. Lipoproteins Purification

Lipoproteins were isolated by isopycnic ultracentrifugation according to the methods described by Himber et al. [22] and McDowell et al. [23] with slight modifications. Briefly, 3.9 mL of pooled plasma...
samples was added with NaBr to \( d = 1.3 \) g/mL (472.2 mg NaBr/mL plasma) in centrifuge tubes (Beckman Coulter, Thin Wall Ultra-Clear, 14 mL, 14 × 95 mm), overlaid with 8.1 mL of a 0.6% NaCl solution (\( d = 1.006 \) g/mL), and centrifuged at 285,000 × g for 48 h at 4 °C in an Optima L90 series ultracentrifuge equipped with a SW40 Ti rotor (Beckman Coulter). Afterwards, VLDL, LDL, and HDL fractions were collected and further purified by a second centrifugation step, performed at 285,000 × g for 24 h in saline solutions at density 1.006, 1.063, and 1.21 g/mL, respectively. Lipoprotein fractions were then collected, desalted (final salt concentration < 5 mM), and concentrated using Amicon Ultra-0.5 mL centrifugal filter units (10 KDa MWCO, Millipore). Protein concentration was determined using DC Protein Assay Kit (Bio-Rad), according to the manufacturer's instructions, using bovine serum albumin as standard. Aliquots of 500 μg (as protein) of LDL and 300 μg (as protein) of VLDL were delipidated by adding ice-cold tri-n-butylphosphate:acetone:methanol (1:12:1) as reported by Mastro and Hall [24]. Delipidated fractions were resolubilized with repeated boiling and sonication passages in 10 mM Mastro and Hall [24]. Delipidated fractions were resolubilized with repeated boiling and sonication passages in 10 mM Tris buffer containing 4% CHAPS (w/v) and 1% DTT (w/v). After cooling to room temperature, samples were diluted with a solution containing 8M urea, 4% CHAPS, 1% DTT, and 0.4% carrier ampholytes and subjected to further sonication passages followed by 2-DE. 50 μg (as protein) of native HDL fraction were solubilized for 2-DE analysis as reported above for LDL and VLDL delipidated fractions.

2.3. 2-DE Analysis. 2-DE was performed as previously described [20]. Briefly, samples were applied to 70 mm IPG strips (pH 4–7, Bio-Rad), by overnight rehydration loading at 20°C, and subsequently focused at 50 μA/IPG strip for 22 kVh at 20°C. After focusing, proteins were in-gel reduced by incubating IPG strips with a 50 mM Tris buffer containing 6 M urea, 30% glycerol (v/v), 3% SDS (w/v) and 1% DTT (w/v), followed by in-gel alkylation, using the same solution containing 2.5% iodoacetamide (w/v) in place of DTT. Each step was performed keeping strips under continuous shaking for 15 minutes. Then, IPG strips were sealed, with 0.5% low melting point agarose (w/v) in SDS running buffer, at the top of second dimension gels (8 cm × 7 cm × 0.1 cm). SDS-PAGE was carried out on 15% T/3% C polyacrylamide gels at 50 V for 15 minutes and subsequently at 150 V for about 90 minutes. Then, gels were fixed in 30% ethanol (v/v), 2% phosphoric acid (v/v) for 1 h, washed twice in 2% phosphoric acid (v/v) solution for 10 minutes, equilibrated in 18% ethanol (v/v) and 2% phosphoric acid (v/v), and 15% ammonium sulfate (w/v) solution for 30 minutes, and stained in the same solution added with 0.02% Coomasie Brilliant Blue G-250 (w/v) for 48 h. Gel images were acquired by using GS-800 calibrated densitometer (Bio-Rad) at 36.3 μm resolution. Image analyses were performed using PD-Quest 2-D analysis software V 8.0.1 (Bio-Rad). Each spot was assigned a relative value corresponding to the single spot volume compared to the volume of all spots in the gel, following background subtraction and normalization between gels. In particular, in the adopted normalization method, the raw quantity of each spot in a member gel was divided by the total quantity of all the spots in that gel that have been included in the Master.

2.4. In-Gel Digestion and MALDI-TOF MS Analysis. Spots of interest were excised with sterile pipette tips, destained with a solution containing 2.5 mM NH₄HCO₃ and 50% acetonitrile (v/v), dehydrated with 100% acetonitrile, and dried at room temperature before proteolytic treatment. Tryptic digestion was performed by incubating dried spots in 5 mM NH₄HCO₃ buffer containing 10 ng/μl trypsin overnight at 37°C. The resulting peptides were mixed with an equal volume of α-cyano-4-hydroxycinnamic acid saturated solution (40% acetonitrile (v/v) and 0.1% trifluoroacetic acid (v/v)) and applied as a microcrystalline thin film onto a stainless steel 96-spot MALDI target. Mass analyses were performed using a MALDI micro-MX-mass-spectrometer (Waters), according to the tuning procedures suggested by the manufacturer. Peak lists were generated using Protein Lynx Global Server v.2.2.5 (Waters) and searched against the Swiss-Prot human database (version 57.4) using Mascot (http://www.matrixscience.com). Research parameters included taxa (Homo sapiens), trypsin digest, monoisotopic peptide masses, iodoacetamide modifications, one missed cleavage by trypsin, and a mass deviation of 50 ppm. Only protein identifications with significant Mascot scores (P < 0.05) were taken into consideration.

2.5. Western Blotting Analysis. Western blotting analyses on proteins resolved by SDS-PAGE were performed as previously described [20]. Briefly, resolved proteins were electroblotted onto Hybond-P PVDF membranes (GE Healthcare) at 250 mA for 1.5 hours. Afterwards, membranes were incubated with blocking solution (PBS, 0.1% Tween-20, 3% nonfat dry milk) for 1 h at room temperature followed by overnight incubation at 4°C with a monoclonal anti-SAA antibody (Abcam, Ab81483) diluted 1:1000 or a polyclonal anti-apo AI antibody (Millipore, AB740) diluted 1:8000 with blocking solution. Then, after 30 minutes washing (PBS, 0.1% Tween-20), membranes were incubated with HRP-conjugated secondary antibody solution for 1 h at room temperature. Following further membrane washing, proteins were revealed by enhanced chemiluminescence using ChemiDoc XRS System (Bio-Rad). Densitometric analysis was performed using Quantity One 4.6.3 software (Bio-Rad).

2.6. Statistical Analysis. Student’s t-test for unpaired samples was performed to compare exchangeable apolipoproteins expression in each purified lipoprotein fraction among atherosclerotic patients and healthy controls, using the software package SigmaStat 3 (Systat Software). Significance was set at \( P < 0.05 \).

3. Results

3.1. Mapping of Exchangeable Apolipoproteins from VLDL, LDL, and HDL Fractions. 2-DE combined with Mass Spectrometry was applied to identify VLDL, LDL, and HDL apolipoproteins from patients undergoing carotid endarterectomy and healthy normolipidemic subjects.
According to echo-Doppler analysis, patients selected for surgery had either a high-grade carotid stenosis (>70%) or an ulcerated lesion. Since apo B100 is the most abundant apolipoprotein of both LDL and VLDL, representing up to 95% of their protein moiety, large amounts of LDL and VLDL were processed in order to allow the detection and identification also of less abundant apolipoproteins. Furthermore, due to the high lipid/protein ratio in both lipoprotein classes, a delipidation step was mandatory.

Reproducible 2-DE maps of exchangeable apolipoproteins from VLDL, LDL, and HDL fractions were obtained (Figure 1). The adopted fractionation procedure, which included an isopycnic gradient ultracentrifugation followed by an additional washing step, allowed high purification yields of all lipoprotein fractions. As a matter of fact, no albumin or additional plasma proteins were detectable in 2-DE gels after Coomassie Brilliant Blue G-250 staining. Moreover, western blotting analysis of the HDL fraction did not reveal any apolipoprotein B-100 contamination (data not shown).

Almost all the resolved protein spots were identified by peptide mass fingerprinting (Table 2). In more detail, we identified 2 isoforms of apo J, 2 isoforms of apo AIV, 5 isoforms of apo E, 6 isoforms of apo AI, 3 isoforms of apo D, 2 isoforms of acute phase serum amyloid A protein, 1 isoform of apo CII and 2 isoforms of apo CIII, in both VLDL and LDL fractions. Due to its high molecular mass (about 500 kDa) and hydrophobicity, apo B100 was not detectable in any VLDL or LDL 2-DE maps. Regarding to HDL, 3 isoforms of apo E, 6 of apo AI, 3 of apo D, 2 of AP SAA, 1 of apo CII, and 2 of apo CIII were identified.

3.2. Differential Apolipoproteins Expression Analysis. Differential expression analysis was performed on VLDL, LDL, and HDL fractions from 4 pooled plasma samples of 79 patients having severe atherosclerosis and 4 pooled plasma samples of 57 healthy volunteers revealing no differences in the relative abundance of all identified apolipoproteins (Figure 2) with the exception of AP SAA that was more abundant (2.3-, 14.0-, and 1.5-fold in VLDL, LDL, and HDL fractions, resp.) in patients \( (P = 0.001, P = 0.003, \text{and } P = 0.045, \text{for VLDL, LDL, and HDL fractions, resp.}) \) (Figure 3). Differential AP SAA expression was confirmed by western blotting analysis.
| Apolipoprotein | No. of isoforms | Accession no. | Nominal mass (Da) | p|l | Start | End | Observed (expt.)b | Mr. (exp.)b | Mr. (calc.)c | Delta | Miss | Unique peptidec | Protein scoree | Prot. Seq. Cov. (%)f 
|----------------|----------------|--------------|------------------|---|---|------|---|-------------------|-----------|-----------|-------|------|----------------|----------------|----------------|
| Apo AI         | 6              | gi|90808664     | 28061           | 5.27 | 1-10 | 1226.6349 | 1225.6276 | 0.0913 | 0 | --.DEPPQPSPWDR.V | 209 | 48 |
|               |                |              |                  | 32 | 45 | 1635.0740 | 1634.0667 | 1633.8311 | 0.2356 | 0 | K.SELTIQLNALFQDK.I | 180 | 44 |
|               |                |              |                  | 46 | 58 | 1407.9354 | 1406.9281 | 1406.7041 | 0.2240 | 0 | K.IGENVTYAGDLQK.K | 82 | 68 |
|               |                |              |                  | 60 | 70 | 1311.9730 | 1310.9657 | 1310.7394 | 0.2135 | 0 | K.TVFPATLHEL.I | 180 | 44 |
|               |                |              |                  | 93 | 103 | 1235.8699 | 1234.8626 | 1234.6539 | 0.1957 | 0 | K.LLPHANEVSQK.I | 180 | 44 |
|               |                |              |                  | 115 | 123 | 104.7449 | 103.7376 | 103.5213 | 0.1765 | 0 | K.RLYLALVQIK.L | 180 | 44 |
| Apo AIV        | 2              | gi|178779       | 43358           | 5.22 | 1-19 | 2203.1370 | 2202.1297 | 2202.0627 | 0.0670 | 0 | --.TQOPQPOQDEPSPTLTFQKV.E | 82 | 68 |
|               |                |              |                  | 20 | 30 | 1286.6555 | 1285.6482 | 1285.5826 | 0.0656 | 0 | K.ESSLSSYWSAK.T | 82 | 68 |
|               |                |              |                  | 56 | 76 | 2233.2048 | 2232.1961 | 2232.0534 | 0.0613 | 0 | K.TAAAMSTYGFTDQVLK.GE | 180 | 44 |
|               |                |              |                  | 56 | 79 | 2548.3137 | 2537.3064 | 2536.2591 | 0.2340 | 1 | K.TAAAMSTYGFTDQVLK.G | 180 | 44 |
| Apo CII        | 1              | gi|1277707    | 8909           | 4.66 | 1-19 | 2023.1370 | 2022.1297 | 2022.0627 | 0.0670 | 0 | --.TQOPQPOQDEPSPTLTFQKV.E | 82 | 68 |
|               |                |              |                  | 20 | 30 | 1286.6555 | 1285.6482 | 1285.5826 | 0.0656 | 0 | K.ESSLSSYWSAK.T | 82 | 68 |
|               |                |              |                  | 56 | 76 | 2233.2048 | 2232.1961 | 2232.0534 | 0.0613 | 0 | K.TAAAMSTYGFTDQVLK.GE | 180 | 44 |
| Apo CIII       | 2              | gi|18972736   | 8759           | 4.72 | 1-17 | 1907.0851 | 1906.0778 | 1905.8488 | 0.2290 | 0 | --.SEADASLSSFMQGQK.H | 71 | 64 |
|               |                |              |                  | 25 | 40 | 1717.0728 | 1716.0655 | 1715.8438 | 0.2217 | 0 | K.HLSSQVESQVAQQQR.G | 71 | 64 |
|               |                |              |                  | 41 | 51 | 1196.7615 | 1195.7542 | 1195.5274 | 0.1669 | 0 | K.RGWVTDGFLSK.D | 71 | 64 |
|               |                |              |                  | 41 | 58 | 2076.2444 | 2075.2371 | 2074.9964 | 0.2371 | 1 | K.RGWVTDGFLSKDYWSTV.KD | 71 | 64 |
| Apo D          | 3              | gi|114034      | 21547          | 5.06 | 28-41 | 1657.8419 | 1656.8346 | 1656.5766 | 0.0780 | 0 | K.CPNPPQENFNDVKN.K | 50 | 22 |
|               |                |              |                  | 46 | 60 | 1883.0264 | 1882.0191 | 1881.9261 | 0.0930 | 0 | K.WYEIEKPTTFENG.C | 50 | 22 |
|               |                |              |                  | 52 | 60 | 1034.6072 | 1033.5999 | 1033.5193 | 0.0807 | 0 | K.IPTTFENG.C | 50 | 22 |
|               |                |              |                  | 152 | 164 | 1423.8282 | 1422.8209 | 1422.7354 | 0.0855 | 0 | K.NPNLPPETVDSLK.N | 50 | 22 |
| Apolipoprotein | No. of isoforms | Accession no. | Nominal mass | pl | Start | End | Observed<sup>a</sup> Mr. (expt.)<sup>b</sup> | Mr. (calc.)<sup>c</sup> | Delta | Miss | Unique peptide<sup>d</sup> | Protein score<sup>e</sup> | Prot. Seq. Cov. (%)<sup>f</sup> |
|---------------|----------------|--------------|--------------|----|-------|-----|-----------------|-----------------|-------|------|-----------------------|----------------|---------------------|
| Apo E         | 5              | gi|178853       | 36185        | 5.81 | 34   | 43  | 1247.6713 1246.6640 1246.5691 | 0.0950 | 0 | R.QQTEWGQSGQR.W | R.QQTHMLDVMQDHFSR.A | 90 30 |
|               |                |              |              |    |       |     | 34 43 1247.6713 1246.6640 1246.5691 | 0.0950 | 0 | R.WVQTLSEQVQEEILSSQVTQEL.R.A | R.QQTHMLDVMQDHFSR.A |         |
|               |                |              |              |    |       |     | 57 79 2730.4333 2729.4260 2729.3872 | 0.0388 | 0 | K.SELEEQTLPVAETR.A | R.WVQTLSEQVQEEILSSQVTQEL.R.A |         |
|               |                |              |              |    |       |     | 208 224 1752.9147 1751.9074 1751.9642 | −0.0568 | 1 | R.VRAATVGSAGQPLQER.A | R.WVQTLSEQVQEEILSSQVTQEL.R.A |         |
|               |                |              |              |    |       |     | 210 224 1497.9037 1496.8964 1496.7947 | 0.1017 | 0 | R.AATVGSAGQPLQER.A | R.WVQTLSEQVQEEILSSQVTQEL.R.A |         |
|               |                |              |              |    |       |     | 259 269 1313.8163 1312.8090 1312.7099 | 0.0992 | 1 | K.SELEEQTLPVAETR.A | R.WVQTLSEQVQEEILSSQVTQEL.R.A |         |
|               |                |              |              |    |       |     | 270 278 1033.5950 1032.5877 1032.5352 | 0.0525 | 0 | R.LQAEAFQR.L | R.AATVGSAGQPLQER.A |         |
|               |                |              |              |    |       |     | 281 292 1536.8112 1535.8039 1535.7079 | 0.0961 | 0 | K.SWFEPLVEDMQ.R | R.AATVGSAGQPLQER.A |         |
|               |                |              |              |    |       |     | 29 43 1873.0469 1872.0396 1871.8407 | 0.1989 | 0 | R.QQTHMLDVMQDHFSR.A | R.J338305 |         |
|               |                |              |              |    |       |     | 44 55 1393.8494 1392.8421 1392.6885 | 0.1536 | 0 | K.SELEEQTLPVAETR.A | R.J338305 |         |
|               |                |              |              |    |       |     | 2001.421 1999.1348 1998.9588 | 0.1760 | 0 | R.EJQVDDSTNNPSQAK.L | R.J338305 |         |
|               |                |              |              |    |       |     | 168 183 1762.9714 1761.9641 1761.8203 | 0.1438 | 0 | R.EJQVDDSTNNPSQAK.L | R.EJQVDDSTNNPSQAK.L |         |
|               |                |              |              |    |       |     | 187 197 1288.7798 1287.7725 1287.6306 | 0.1499 | 0 | R.EJQVDDSTNNPSQAK.L | R.EJQVDDSTNNPSQAK.L |         |
|               |                |              |              |    |       |     | 270 286 1874.1448 1873.1375 1872.9833 | 0.1542 | 0 | K.LFDSQPPQITVTVVQK.R | R.EJQVDDSTNNPSQAK.L |         |
| APSAA         | 2              | gi|225986       | 11675        | 5.89 | 2    | 15  | 1550.6927 1549.6854 1549.7202 | −0.0347 | 0 | R.SFFSFLAEFDGAR.D | R.SFFSFLAEFDGAR.D |         |
|               |                |              |              |    |       |     | 26 39 1670.7418 1669.7345 1669.7848 | −0.0503 | 1 | R.EANYIGSDYFHR.A | R.SFFSFLAEFDGAR.D |         |
|               |                |              |              |    |       |     | 47 62 1456.6875 1455.6802 1453.7106 | −0.0304 | 0 | R.GPGVWAAEISDAR.E | R.EANYIGSDYFHR.A |         |
|               |                |              |              |    |       |     | 68 87 2177.8303 2176.8230 2176.9562 | −0.1332 | 0 | R.FGHHGDNLQADQANNEWGR.S | R.GPGVWAAEISDAR.E |         |

<sup>a</sup>m/z value of the observed peak in MS analysis; <sup>b</sup>molecular weight expected for peptide; <sup>c</sup>molecular weight calculated; <sup>d</sup>unique peptides identified in the spot; <sup>e</sup>Mascot score; <sup>f</sup>percentage of protein coverage.
on each lipoprotein fraction using apo AI levels for data normalization ($P = 0.03$, $P = 0.03$, and $P = 0.05$, for VLDL, LDL, and HDL fractions, resp.) (Figure 4). To further corroborate these preliminary observations, the same western blotting assay was performed on a randomly chosen sample from each group (Figure 4).

4. Discussion

By means of two-dimensional electrophoresis (2-DE) coupled with Mass Spectrometry (MS) analysis on plasma-purified VLDL, LDL, and HDL fractions we were able to identify acute phase serum amyloid A protein (AP SAA) as a potential marker of advanced carotid atherosclerosis. The protein moiety of the different lipoprotein species is largely responsible for their functions, being involved in several metabolic events, such as recognition by specific receptors on cell surfaces or regulation of the activity of various enzymes [6]. Obtaining detailed information about apolipoprotein composition may contribute to revealing their role in atherogenesis. To date, only few studies have dealt with lipoproteomics in relation to atherosclerosis or atherosclerosis-related diseases, with most of them being performed on HDL from coronary artery disease (CAD) patients [10–13].

This is the first report focusing on differential apolipoprotein expression in atherosclerotic patients undergoing carotid endarterectomy compared to healthy controls. As the adopted method is very labour intensive, we decided to set it up on randomly combined pooled plasma samples. In our opinion, this is the major limitation of the study, since each data reported represents an average value from 15 to 20 samples and a measure of how much variation or dispersion from the average exists is missing. On the other hand, this approach allowed for comparing levels of the exchangeable apolipoproteins in each lipoprotein fraction from a noteworthy number of patients and controls (79 patients and 57 controls). Indeed, the preliminary results obtained from differential protein expression analysis may represent a useful starting point for further, more specific analyses that could be carried out on each sample separately (e.g., ELISA on plasma samples and plaque extracts, and immunohistochemistry on endarterectomy specimens).

The apolipoprotein profile of VLDL, LDL, and HDL fractions, obtained from patients with advanced atherosclerosis was analysed, identifying 23 different protein isoforms by peptide mass fingerprinting. Moreover, we compared the obtained profiles with those from healthy volunteers.

The adopted purification procedure provided highly purified lipoprotein fractions as confirmed by the absence of

---

**Figure 2**: Relative amounts of exchangeable apolipoproteins in VLDL (a), LDL (b), and HDL (c) fractions representative of both patients and controls. Data were obtained by image analysis on 2-DE maps from all examined pooled plasma samples (4 obtained from patients and 4 from healthy controls) using PD-Quest analysis software V 8.0.1. Because of its high percentage in respect to the other apolipoproteins, apo AI was omitted in the panels corresponding to LDL (b) and HDL (c) fractions, being 72.9 ± 9.8% and 91.5 ± 3.7%, respectively. Relative amount of AP SAA is reported in Figure 3. Data are expressed as mean ± SD.
Figure 3: Relative amount of AP SAA in VLDL, LDL, and HDL fractions. AP SAA was found differentially expressed in all purified fractions in patients compared to controls ($P = 0.001$, $P = 0.003$, and $P = 0.045$, for VLDL, LDL, and HDL fractions, resp.). Data were obtained by image analysis on 2-DE maps from 4 pooled plasma samples obtained from patients and 4 from healthy controls using PD-Quest analysis software V 8.0.1. Data are expressed as mean ± SD.

Figure 4: One-dimensional western blotting analysis. Bar charts reporting AP SAA and apo AI expression in VLDL, LDL, and HDL fractions isolated from 4 pooled plasma samples obtained from 57 controls (lanes 1–4) and 4 from 79 patients (lanes 5–8). Following data normalization for apo AI levels, AP SAA was confirmed as differentially expressed in all purified fractions from patients compared to controls ($P = 0.03$, $P = 0.03$, and $P = 0.05$, for VLDL, LDL, and HDL fractions, resp.). Results obtained on a randomly chosen sample from controls group (lane 9) and from patients group (lane 10) are shown. 10 µg and 1 µg of proteins were loaded for AP SAA and apo AI immunodetection, respectively.
plasma proteins as well as of apo B-100 in HDL (assessed by western blotting). Furthermore, due to the high number of resolved protein isoforms and the low limit of detection, 2-DE has proven to have high resolution and sensitivity.

Image analysis allowed for identifying AP SAA as differentially expressed in atherosclerotic patients. Its levels were higher in all lipoprotein fractions, increasing up to fourteenfold in atherosclerotic patients LDL fraction. Such evidence was confirmed by western blotting analysis on each lipoprotein purified fraction.

Serum amyloid A protein belongs to a family of acute-phase proteins, synthesized primarily in the liver, that circulate mainly associated to HDL. During the acute-phase reaction, plasma AP SAA concentration may increase up to 1000-fold due to an upregulation of its synthesis by inflammatory cytokines or peptide hormone signals [25]. Besides some evidence of an antiatherogenic role in promoting cholesterol efflux from cells [26–30], a plethora of studies have suggested proatherogenic effects for SAA, such as promotion of monocytes and neutrophils chemotaxis [31–33], macrophage foam cells formation [34], stimulation of proinflammatory cytokines secretion by monocytes-macrophages and lymphocytes [33, 35, 36], and induction of endothelial dysfunction [33, 37, 38]. Furthermore, SAA may potentiate prothrombotic events by inducing tissue factor expression [39]. A role for SAA in lipoprotein subendothelial retention has been postulated, since it is known that it could stimulate the synthesis of vascular proteoglycans with an increased LDL-binding affinity [40] and a proteoglycan binding domain on its carboxy-terminal region has been identified [41]. Furthermore, a study on in vivo murine model demonstrated that SAA deposited in atherosclerotic areas at all stages of lesion development and highly correlated with lesion area, apo AI area, apoB-100 area, and perlecan area [42]. Nevertheless, both protein localization [43] and mRNA expression [44] in human atherosclerotic plaques were demonstrated. SAA was also shown to increase in patients with atherosclerosis of the coronary and peripheral arteries [45–50]. Interestingly, Ogasawara et al. evidenced that LDL-associated SAA represents a marker of intravascular inflammation in patients with stable CAD, more sensitive than C-reactive protein, or free SAA [51]. Finally, a strong independent relationship between SAA and future cardiovascular events was demonstrated [52, 53]. All this evidence underlines not only the potential of this protein as a marker of advanced vascular disease but also the mechanisms by which SAA plays a direct role in atherosclerosis development.

Our results further support findings on proatherogenic effects of AP SAA and suggest a role of LDL as AP SAA carrier into the artery wall, where it could exert its noxious effects.

5. Conclusions

Our aim was to evaluate the apolipoprotein expression profiles in VLDL, LDL, and HDL fractions from patients undergoing carotid endarterectomy and healthy normolipidemic subjects by means of 2-DE coupled to Mass Spectrometry. By this approach, for the first time, AP SAA was identified as differentially expressed. Its levels were higher in all lipoprotein fractions, rising up to fourteenfold in LDL from atherosclerotic patients, indicating a potential association between AP SAA and the presence of advanced carotid lesions. Although preliminary, our findings are in accordance with a number of in vitro and in vivo evidence sources for a contributory role of this protein in atherogenesis. The adopted methodological approach was proven to be a powerful tool for identifying lipoprotein-associated markers in cardiovascular research. Further studies are in progress to evaluate the potential of LDL-associated AP SAA as a marker of carotid atherosclerosis as well as the effects of its increase in inducing inflammatory mechanisms underlying plaque development and progression/vulnerability.

Acknowledgments

The authors thank Dr. Giustina Casu Finlayson for the English language revision. This study was supported by Regione Autonoma della Sardegna (P.O.R. Sardegna F.S.E. 2007/2013, Asse IV Capitale Umano, Obiettivo Competitivita Regionale e Occupazione, Asse IV Capitale Umano, Linea di Attivita I.3.1) and by Fondazione Banco di Sardegna (Sassari, Italy).

References

[1] E. Lutgens, R.-J. van Suylen, B. C. Faber et al., “Atherosclerotic plaque rupture: local or systemic process?” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 12, pp. 2123–2130, 2003.
[2] P. Libby, “Inflammation in atherosclerosis,” Nature, vol. 420, no. 6917, pp. 868–874, 2002.
[3] K. J. Williams and I. Tabas, “The response-to-retention hypothesis of early atherogenesis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15, no. 5, pp. 551–562, 1995.
[4] K. Skálen, M. Gustafsson, E. Knutsen Rydberg et al., “Subendothelial retention of atherogenic lipoproteins in early atherosclerosis,” Nature, vol. 417, no. 6890, pp. 750–754, 2002.
[5] A. Jonas and M. C. Phillips, “Lipoprotein structure,” in Biochemistry of Lipids, Lipoprotein and Membranes, D. E. Vance and J. E. Vance, Eds., pp. 485–506, Elsevier, 5th edition, 2008.
[6] V. M. Bolanos-Garcia and R. N. Miguel, “On the structure and function of apolipoproteins: more than a family of lipid-binding proteins,” Progress in Biophysics and Molecular Biology, vol. 83, no. 1, pp. 47–68, 2003.
[7] G. Walldius, I. Jungner, I. Holme, A. H. Aastveit, W. Kolar, and E. Steiner, “High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study,” The Lancet, vol. 358, no. 9298, pp. 2026–2033, 2001.
[8] A. J. Lepedda, E. Zinelu, and M. Formato, “Overview of current proteomic approaches for discovery of vascular biomarkers of atherosclerosis,” in Proteomics—Human Diseases and Protein Functions, T.-K. Man and J. R. Flores, Eds., pp. 3–32, InTech, 2012.
[9] A. von Zychlinski, T. Kleffmann, M. J. A. Williams, and S. P. McCormick, “Proteomics of Lipoprotein(a) identifies a protein complement associated with response to wounding,” Journal of Proteomics, vol. 74, no. 12, pp. 2881–2891, 2011.
[10] T. Vaisar, S. Pennathur, P. S. Green et al., “Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL,” *Journal of Clinical Investigation*, vol. 117, no. 3, pp. 746–756, 2007.

[11] P. S. Green, T. Vaisar, S. Pennathur et al., “Combined statin and nicotinic acid therapy remodels the high-density lipoprotein proteome,” *Circulation*, vol. 118, no. 12, pp. 1259–1267, 2008.

[12] T. Vaisar, P. Mayer, E. Nilsson, X.-Q. Zhao, R. Knopp, and B. J. Prazen, “HDL in humans with cardiovascular disease exhibits a proteomic signature,” *Clinaica Chimica Acta*, vol. 411, no. 13-14, pp. 972–979, 2010.

[13] K. Alwaili, D. Bailey, Z. Awan et al., “The HDL proteome in acute coronary syndromes shifts to an inflammatory profile,” *Biochimica et Biophysica Acta*, vol. 1821, no. 3, pp. 405–415, 2012.

[14] J. Cubedo, T. Padró, R. Alonso, J. Cinca, P. Mata, and L. Badimon, “Differential proteomic distribution of TTR (prealbumin) forms in serum and HDL of patients with high cardiovascular risk,” *Atherosclerosis*, vol. 222, no. 1, pp. 263–269, 2012.

[15] M. Heller, E. Schlappritz, D. Stalder, J.-M. Nuoffer, and A. Haeberli, “Compositional protein analysis of high density lipoproteins in hypercholesterolemia by shotgun LC-MS/MS and probabilistic peptide scoring,” *Molecular and Cellular Proteomics*, vol. 6, no. 6, pp. 1059–1072, 2007.

[16] M. T. Mazura, H. L. Cardasis, D. S. Spellman, A. Liaw, N. A. Yates, and R. C. Hendrickson, “Quantitative analysis of intact apolipoproteins in human HDL by top-down differential mass spectrometry,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 17, pp. 7728–7733, 2010.

[17] J. H. M. Levels, P. Geurts, H. Karlsson et al., “High-density lipoprotein proteome dynamics in human endotoxemia,” *Proteome Science*, vol. 9, article 34, 2011.

[18] P. Davidsson, J. Hulte, B. Fagerberg et al., “A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes,” *Journal of Lipid Research*, vol. 46, no. 9, pp. 1999–2006, 2005.

[19] P. V. Bondarenko, S. L. Cockrill, L. K. Watkins, I. D. Cruzado, and R. D. Macfarlane, “Mass spectral study of polymorphism of the apolipoproteins of very low density lipoprotein,” *Journal of Lipid Research*, vol. 40, no. 3, pp. 543–555, 1999.

[20] A. J. Lepedda, A. Cigliano, G. M. Cherchi et al., “A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries,” *Atherosclerosis*, vol. 203, no. 1, pp. 112–118, 2009.

[21] A. J. Lepedda, A. Zinellu, G. Nieddu et al., “Protein sulfhydryl group oxidation and mixed-disulfide modifications in stable and unstable human carotid plaques,” *Oxidative Medicine and Cellular Longevity*, vol. 2013, Article ID 403973, 8 pages, 2013.

[22] J. Himber, E. Buhler, D. Moll, and U. K. Moser, “Low density lipoprotein for oxidation and metabolic studies. Isolation from small volumes of plasma using a tabletop ultracentrifuge,” *International Journal for Vitamin and Nutrition Research*, vol. 65, no. 2, pp. 137–142, 1995.

[23] I. F. W. McDowell, J. McEneny, and E. R. Trimble, “A rapid method for measurement of the susceptibility to oxidation of low-density lipoprotein,” *Annals of Clinical Biochemistry*, vol. 32, no. 2, pp. 167–174, 1995.

[24] R. Mastro and M. Hall, “Protein delipidation and precipitation by tri-n-butylphosphate, acetone, and methanol treatment for isoelectric focusing and two-dimensional gel electrophoresis,” *Analytical Biochemistry*, vol. 273, no. 2, pp. 313–315, 1999.

[25] V. L. King, J. Thompson, and L. R. Tannock, “Serum amyloid A in atherosclerosis,” *Current Opinion in Lipidology*, vol. 22, no. 4, pp. 302–307, 2011.

[26] S. P. Tam, A. Flexman, J. Hulme, and R. Kisilevsky, “Promoting export of macrophage cholesterol: the physiological role of a major acute-phase protein, serum amyloid A 2.1,” *Journal of Lipid Research*, vol. 43, no. 9, pp. 1410–1420, 2002.

[27] J. A. Stonik, A. T. Remaley, S. J. Demosky, E. B. Neufeld, A. Bocharov, and H. B. Brewer, “Serum Amyloid A promotes ABCA1-dependent and ABCA1-independent lipid efflux from cells,” *Biochemical and Biophysical Research Communications*, vol. 321, no. 4, pp. 936–941, 2004.

[28] S. P. Tam, J. B. Ancsin, R. Tan, and R. Kisilevsky, “Peptides derived from serum amyloid A prevent, and reverse, aortic lipid lesions in apoE−/− mice,” *Journal of Lipid Research*, vol. 46, no. 10, pp. 2091–2101, 2005.

[29] D. R. van der Westhuizen, L. Cai, M. C. DeBeer, and F. C. DeBeer, “Serum amyloid A promotes cholesterol efflux mediated by scavenger receptor B-1,” *Journal of Biological Chemistry*, vol. 280, no. 43, pp. 35890–35895, 2005.

[30] R. Kisilevsky, S. P. Tam, and J. B. Ancsin, “The anti-atherogenic potential of serum amyloid A peptides,” *Current Opinion in Investigational Drugs*, vol. 9, no. 3, pp. 265–273, 2008.

[31] R. Badolato, J. M. Wang, W. J. Murphy et al., “Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes,” *Journal of Experimental Medicine*, vol. 180, no. 1, pp. 203–209, 1994.

[32] Y. L. Ha, D. K. Sang, W. S. Jae et al., “Serum amyloid A induces CCL2 production via formyl peptide receptor-like-1 mediated signaling in human monocytes,” *Journal of Immunology*, vol. 181, no. 6, pp. 4332–4339, 2008.

[33] Z. Dong, T. Wu, W. Qin et al., “Serum amyloid A directly accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice,” *Molecular Medicine*, vol. 17, no. 11, pp. 1357–1364, 2011.

[34] S. Hua, C. Song, C. S. Freedman, and P. K. Wittig, “Serum amyloid A stimulates macrophage foam cell formation via lectin-like oxidized low-density lipoprotein receptor 1 upregulation,” *Biochemical and Biophysical Research Communications*, vol. 433, no. 1, pp. 18–23, 2013.

[35] C. J. Furlaneto and A. Campa, “A novel function of serum amyloid A: a potent stimulus for the release of tumor necrosis factor-α, interleukin-1β, and interleukin-8 by human blood neutrophil,” *Biochemical and Biophysical Research Communications*, vol. 268, no. 2, pp. 405–408, 2000.

[36] C. Song, K. Hsu, E. Yamen et al., “Serum amyloid A induction of cytokines in monocytes/macrophages and lymphocytes,” *Atherosclerosis*, vol. 207, no. 2, pp. 374–383, 2009.

[37] S. Hua, C. Song, C. L. Geacey, S. B. Freedman, and P. K. Wittig, “A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis,” *Redox Report*, vol. 14, no. 5, pp. 187–196, 2009.

[38] P. K. Wittig, C. Song, K. Hsu et al., “The acute-phase protein serum amyloid A induces endothelial dysfunction that is inhibited by high-density lipoprotein,” *Free Radical Biology and Medicine*, vol. 51, no. 7, pp. 1390–1398, 2011.

[39] C. Song, Y. Shen, E. Yamen et al., “Serum amyloid A may potentiate prothrombotic and proinflammatory events in acute coronary syndromes,” *Atherosclerosis*, vol. 202, no. 2, pp. 596–604, 2009.
[40] P. G. Wilson, J. C. Thompson, N. R. Webb, F. C. DeBeer, V. L. King, and L. R. Tannock, "Serum amyloid A, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-atherogenic manner," American Journal of Pathology, vol. 173, no. 6, pp. 1902–1910, 2008.

[41] J. B. Ancsin and R. Kisilevsky, "Serum amyloid A peptide interactions with glycosaminoglycans. Evaluation by affinity chromatography," Methods in Molecular Biology, vol. 171, pp. 449–456, 2001.

[42] K. D. O’Brien, T. O. McDonald, V. Kunjathoor et al., "Serum amyloid A and lipoprotein retention in murine models of atherosclerosis," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 4, pp. 785–790, 2005.

[43] T. Yamada, T. Kakihara, T. Kamishima, T. Fukuda, and T. Kawai, "Both acute phase and constitutive serum amyloid A are present in atherosclerotic lesions," Pathology International, vol. 46, no. 10, pp. 797–800, 1996.

[44] R. L. Meek, S. Urieli-Shoval, and E. P. Benditt, "Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function," Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 8, pp. 3186–3190, 1994.

[45] G. Liuzzo, L. M. Biasucci, J. R. Gallimore et al., "The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina," The New England Journal of Medicine, vol. 331, no. 7, pp. 417–424, 1994.

[46] A. I. Fyfe, L. S. Rothenberg, F. C. DeBeer, R. M. Cantor, J. I. Rotter, and A. J. Lusis, "Association between serum amyloid A proteins and coronary artery disease: evidence from two distinct arteriosclerotic processes," Circulation, vol. 96, no. 9, pp. 2914–2919, 1997.

[47] M. Erren, H. Reinecke, R. Junker et al., "Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 10, pp. 2355–2363, 1999.

[48] N. Rifai, R. Joubran, H. Yu, M. Asmi, and M. Jouma, "Inflammatory markers in men with angiographically documented coronary heart disease," Clinical Chemistry, vol. 45, no. 11, pp. 1967–1973, 1999.

[49] P. Joussilhati, V. Salomaa, V. Rasi, E. Vahtera, and T. Palosuo, "The association of c-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease—baseline findings of the PAIS project," Atherosclerosis, vol. 156, no. 2, pp. 451–456, 2001.

[50] J. R. Delanghe, M. R. Langlois, D. de Bacquer et al., "Discriminative value of serum amyloid A and other acute-phase proteins for coronary heart disease," Atherosclerosis, vol. 160, no. 2, pp. 471–476, 2002.

[51] K. Ogasawara, S. Mashiba, Y. Wada et al., "A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease," Atherosclerosis, vol. 174, no. 2, pp. 349–356, 2004.

[52] B. D. Johnson, K. E. Kip, O. C. Marroquin et al., "Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: The National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE)," Circulation, vol. 109, no. 6, pp. 726–732, 2004.

[53] K. W. J. Lee, J. S. Hill, K. R. Walley, and J. J. Frohlich, "Relative value of multiple plasma biomarkers as risk factors for coronary artery disease and death in an angiography cohort," Canadian Medical Association Journal, vol. 174, no. 4, pp. 461–466, 2006.